Andrew Kraft to Humans
This is a "connection" page, showing publications Andrew Kraft has written about Humans.
Connection Strength
0.986
-
The long noncoding RNA H19 regulates tumor plasticity in neuroendocrine prostate cancer. Nat Commun. 2021 12 21; 12(1):7349.
Score: 0.030
-
Sustained response to pembrolizumab in recurrent perivascular epithelioid cell tumor with elevated expression of programmed death ligand: a case report. J Med Case Rep. 2021 Jul 24; 15(1):400.
Score: 0.029
-
"Root"ing for successful T-ALL treatment. Blood. 2021 05 06; 137(18):2422-2423.
Score: 0.029
-
A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer. 2021 03 15; 127(6):894-904.
Score: 0.028
-
Small-Molecule-Targeting Hairpin Loop of hTERT Promoter G-Quadruplex Induces Cancer Cell Death. Cell Chem Biol. 2019 08 15; 26(8):1110-1121.e4.
Score: 0.025
-
Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase. Mol Cancer Ther. 2018 12; 17(12):2710-2721.
Score: 0.024
-
Angiosarcoma treated successfully with anti-PD-1 therapy - a case report. J Immunother Cancer. 2017 07 18; 5(1):58.
Score: 0.022
-
Quantitative meta-analytic approaches for the systematic synthesis of data and hazard identification: A case study of decreased pain sensitivity due to trimethylbenzene exposure. Environ Res. 2017 10; 158:598-609.
Score: 0.022
-
Targeting the PIM protein kinases for the treatment of a T-cell acute lymphoblastic leukemia subset. Oncotarget. 2017 May 02; 8(18):30199-30216.
Score: 0.022
-
PIM Kinase Inhibitors Kill Hypoxic Tumor Cells by Reducing Nrf2 Signaling and Increasing Reactive Oxygen Species. Mol Cancer Ther. 2016 07; 15(7):1637-47.
Score: 0.020
-
Insulin receptor substrate 1 is a substrate of the Pim protein kinases. Oncotarget. 2016 Apr 12; 7(15):20152-65.
Score: 0.020
-
PIM kinase (and Akt) biology and signaling in tumors. Pharmacol Ther. 2015 Jul; 151:41-9.
Score: 0.019
-
Regulation of prostate stromal fibroblasts by the PIM1 protein kinase. Cell Signal. 2015 Jan; 27(1):135-46.
Score: 0.018
-
Deletion of Pim kinases elevates the cellular levels of reactive oxygen species and sensitizes to K-Ras-induced cell killing. Oncogene. 2015 Jul; 34(28):3728-36.
Score: 0.018
-
The Pim-1 protein kinase is an important regulator of MET receptor tyrosine kinase levels and signaling. Mol Cell Biol. 2014 Jul; 34(13):2517-32.
Score: 0.018
-
Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. Cancer Res. 2013 Jun 01; 73(11):3402-11.
Score: 0.016
-
Pim kinase inhibitors sensitize prostate cancer cells to apoptosis triggered by Bcl-2 family inhibitor ABT-737. Cancer Res. 2012 Jan 01; 72(1):294-303.
Score: 0.015
-
Combination therapy of recurrent prostate cancer with the proteasome inhibitor bortezomib plus hormone blockade. Cancer Biol Ther. 2011 Jul 15; 12(2):119-24.
Score: 0.015
-
The Pim protein kinases regulate energy metabolism and cell growth. Proc Natl Acad Sci U S A. 2011 Jan 11; 108(2):528-33.
Score: 0.014
-
The BH3 mimetic ABT-737 induces cancer cell senescence. Cancer Res. 2011 Jan 15; 71(2):506-15.
Score: 0.014
-
Regulation of Skp2 levels by the Pim-1 protein kinase. J Biol Chem. 2010 Sep 17; 285(38):29128-37.
Score: 0.014
-
p53-dependent induction of prostate cancer cell senescence by the PIM1 protein kinase. Mol Cancer Res. 2010 Aug; 8(8):1126-41.
Score: 0.014
-
A small molecule inhibitor of Pim protein kinases blocks the growth of precursor T-cell lymphoblastic leukemia/lymphoma. Blood. 2010 Jan 28; 115(4):824-33.
Score: 0.013
-
Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells. Mol Cancer Ther. 2009 Jun; 8(6):1473-83.
Score: 0.013
-
PIM1 protein kinase regulates PRAS40 phosphorylation and mTOR activity in FDCP1 cells. Cancer Biol Ther. 2009 May; 8(9):846-53.
Score: 0.013
-
ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem. 2008 Sep 05; 283(36):25003-13.
Score: 0.012
-
Hypoxia-inducible factor-2alpha regulates the expression of TRAIL receptor DR5 in renal cancer cells. Carcinogenesis. 2008 Sep; 29(9):1734-41.
Score: 0.012
-
Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region. Mol Cancer Ther. 2008 May; 7(5):1091-100.
Score: 0.012
-
Cell cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy. Cancer Biol Ther. 2007 Jul; 6(7):1067-73.
Score: 0.011
-
Negative regulation of Pim-1 protein kinase levels by the B56beta subunit of PP2A. Oncogene. 2007 Aug 02; 26(35):5145-53.
Score: 0.011
-
Regulation of RUNX1/AML1 during the G2/M transition. Leuk Res. 2007 Jun; 31(6):839-51.
Score: 0.010
-
Pim family kinases enhance tumor growth of prostate cancer cells. Mol Cancer Res. 2005 Aug; 3(8):443-51.
Score: 0.010
-
The proteasome inhibitor bortezomib sensitizes cells to killing by death receptor ligand TRAIL via BH3-only proteins Bik and Bim. Mol Cancer Ther. 2005 Mar; 4(3):443-9.
Score: 0.009
-
RAS, MYC, and sensitivity to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 2005 Feb 15; 65(4):1615-6; author reply 1616-7.
Score: 0.009
-
Phorbol ester treatment of K562 cells regulates the transcriptional activity of AML1c through phosphorylation. J Biol Chem. 2004 Dec 17; 279(51):53116-25.
Score: 0.009
-
Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis. Cancer Res. 2004 Jun 01; 64(11):3922-7.
Score: 0.009
-
The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene. 2003 Aug 07; 22(32):4953-63.
Score: 0.008
-
An XBP1s-PIM-2 positive feedback loop controls IL-15-mediated survival of natural killer cells. Sci Immunol. 2023 03 17; 8(81):eabn7993.
Score: 0.008
-
Pim-1 protein kinase is nuclear in Burkitt's lymphoma: nuclear localization is necessary for its biologic effects. Anticancer Res. 2003 Jan-Feb; 23(1A):167-78.
Score: 0.008
-
OER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma. Cancer. 2022 10 01; 128(19):3516-3522.
Score: 0.008
-
Transitioning ifosfamide chemotherapy regimens to the ambulatory setting: reviewing cost savings and safety profile. Support Care Cancer. 2022 Mar; 30(3):2755-2766.
Score: 0.007
-
The human brm protein is cleaved during apoptosis: the role of cathepsin G. Proc Natl Acad Sci U S A. 2001 Mar 27; 98(7):3814-9.
Score: 0.007
-
Distinct domains of the human granulocyte-macrophage colony-stimulating factor receptor alpha subunit mediate activation of Jak/Stat signaling and differentiation. Blood. 2001 Mar 15; 97(6):1662-70.
Score: 0.007
-
Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J Biol Chem. 2001 Apr 06; 276(14):10767-74.
Score: 0.007
-
Regulation of dual-specificity phosphatases M3/6 and hVH5 by phorbol esters. Analysis of a delta-like domain. J Biol Chem. 2000 Oct 13; 275(41):31755-62.
Score: 0.007
-
PIM Kinase Inhibitors Block the Growth of Primary T-cell Acute Lymphoblastic Leukemia: Resistance Pathways Identified by Network Modeling Analysis. Mol Cancer Ther. 2020 09; 19(9):1809-1821.
Score: 0.007
-
A novel study evaluation strategy in the systematic review of animal toxicology studies for human health assessments of environmental chemicals. Environ Int. 2020 08; 141:105736.
Score: 0.007
-
PIM protein kinases regulate the level of the long noncoding RNA H19 to control stem cell gene transcription and modulate tumor growth. Mol Oncol. 2020 05; 14(5):974-990.
Score: 0.007
-
The role of the Smad3 protein in phorbol ester-induced promoter expression. J Biol Chem. 1999 Dec 24; 274(52):36987-94.
Score: 0.007
-
Treatment of patients with metastatic melanoma with bryostatin-1--a phase II study. Melanoma Res. 1999 Dec; 9(6):599-606.
Score: 0.007
-
Phosphorylation of DEPDC5, a component of the GATOR1 complex, releases inhibition of mTORC1 and promotes tumor growth. Proc Natl Acad Sci U S A. 2019 10 08; 116(41):20505-20510.
Score: 0.006
-
Vascular endothelial growth factor in the sera and effusions of patients with malignant and nonmalignant disease. Cancer. 1999 Jan 01; 85(1):178-87.
Score: 0.006
-
Targeting PIM Kinase with PD1 Inhibition Improves Immunotherapeutic Antitumor T-cell Response. Clin Cancer Res. 2019 02 01; 25(3):1036-1049.
Score: 0.006
-
Activation of the mitogen-activated protein kinase pathway in U937 leukemic cells induces phosphorylation of the amino terminus of the TATA-binding protein. Cell Growth Differ. 1998 Aug; 9(8):667-76.
Score: 0.006
-
Cytoplasmic domains of the human granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor beta chain (hbetac) responsible for human GM-CSF-induced myeloid cell differentiation. J Biol Chem. 1998 Jul 31; 273(31):19411-8.
Score: 0.006
-
Conditional expression of mitogen-activated protein kinase phosphatase-1, MKP-1, is cytoprotective against UV-induced apoptosis. Proc Natl Acad Sci U S A. 1998 Mar 17; 95(6):3014-9.
Score: 0.006
-
Inhibition of caspases by cytokine response modifier A blocks androgen ablation-mediated prostate cancer cell death in vivo. Cancer Res. 1998 Feb 15; 58(4):834-9.
Score: 0.006
-
Treatment of human prostate cancer cells with dolastatin 10, a peptide isolated from a marine shell-less mollusc. Prostate. 1998 Feb 15; 34(3):175-81.
Score: 0.006
-
Enforced expression of the Mr 33,000 Pim-1 kinase enhances factor-independent survival and inhibits apoptosis in murine myeloid cells. Cancer Res. 1997 Dec 01; 57(23):5348-55.
Score: 0.006
-
Complex regulation of CDK2 during phorbol ester-induced hematopoietic differentiation. Blood. 1997 Nov 01; 90(9):3430-7.
Score: 0.006
-
Hypoxia-Inducible PIM Kinase Expression Promotes Resistance to Antiangiogenic Agents. Clin Cancer Res. 2018 01 01; 24(1):169-180.
Score: 0.006
-
The cytoplasmic domain of granulocyte-macrophage colony-stimulating factor (GM-CSF) receptor alpha subunit is essential for both GM-CSF-mediated growth and differentiation. J Biol Chem. 1997 Jul 11; 272(28):17450-9.
Score: 0.006
-
Conditional expression of the mitogen-activated protein kinase (MAPK) phosphatase MKP-1 preferentially inhibits p38 MAPK and stress-activated protein kinase in U937 cells. J Biol Chem. 1997 Jul 04; 272(27):16917-23.
Score: 0.006
-
The kinase domain of Jak2 mediates induction of bcl-2 and delays cell death in hematopoietic cells. J Biol Chem. 1997 May 09; 272(19):12350-8.
Score: 0.005
-
Cloning and chromosomal location of a novel member of the myotonic dystrophy family of protein kinases. J Biol Chem. 1997 Apr 11; 272(15):10013-20.
Score: 0.005
-
Biological activity of 26-succinylbryostatin 1. Biochim Biophys Acta. 1996 Jul 24; 1312(3):197-206.
Score: 0.005
-
Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. Cancer Res. 1996 Feb 15; 56(4):802-8.
Score: 0.005
-
The role of the transcription factor Sp1 in regulating the expression of the WAF1/CIP1 gene in U937 leukemic cells. J Biol Chem. 1996 Jan 12; 271(2):901-6.
Score: 0.005
-
Activation of Pim Kinases Is Sufficient to Promote Resistance to MET Small-Molecule Inhibitors. Cancer Res. 2015 Dec 15; 75(24):5318-28.
Score: 0.005
-
Constitutively active MAP kinase kinase (MEK1) stimulates SAP kinase and c-Jun transcriptional activity in U937 human leukemic cells. Oncogene. 1995 Dec 07; 11(11):2365-74.
Score: 0.005
-
Inhibitors of cyclin-dependent kinase and cancer. J Mol Med (Berl). 1995 Oct; 73(10):509-14.
Score: 0.005
-
Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2. Cancer Res. 1995 Sep 01; 55(17):3716-20.
Score: 0.005
-
In vitro association between the Jun protein family and the general transcription factors, TBP and TFIIB. Biochem J. 1995 Feb 01; 305 ( Pt 3):967-74.
Score: 0.005
-
The PIM family of oncoproteins: small kinases with huge implications in myeloid leukemogenesis and as therapeutic targets. Oncotarget. 2014 Sep 30; 5(18):8503-14.
Score: 0.005
-
Reducing CD73 expression by IL1?-Programmed Th17 cells improves immunotherapeutic control of tumors. Cancer Res. 2014 Nov 01; 74(21):6048-59.
Score: 0.005
-
Metabolic dysfunction consistent with premature aging results from deletion of Pim kinases. Circ Res. 2014 Jul 18; 115(3):376-87.
Score: 0.004
-
Mapping the intracytoplasmic regions of the alpha granulocyte-macrophage colony-stimulating factor receptor necessary for cell growth regulation. J Biol Chem. 1994 May 20; 269(20):14607-13.
Score: 0.004
-
A peptide encoding the c-Jun delta domain inhibits the activity of a c-jun amino-terminal protein kinase. J Biol Chem. 1994 Apr 15; 269(15):11186-91.
Score: 0.004
-
The 2014 Surgeon General's report: "The health consequences of smoking--50 years of progress": a paradigm shift in cancer care. Cancer. 2014 Jul 01; 120(13):1914-6.
Score: 0.004
-
Phase I trial of weekly docetaxel, total androgen blockade, and image-guided intensity-modulated radiotherapy for localized high-risk prostate adenocarcinoma. Clin Genitourin Cancer. 2014 Apr; 12(2):80-6.
Score: 0.004
-
A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. Anticancer Drugs. 2013 Aug; 24(7):743-53.
Score: 0.004
-
A critical role for the cytoplasmic domain of the granulocyte-macrophage colony-stimulating factor alpha receptor in mediating cell growth. Cell Growth Differ. 1993 Jun; 4(6):523-31.
Score: 0.004
-
Pim1 serine/threonine kinase regulates the number and functions of murine hematopoietic stem cells. Stem Cells. 2013 Jun; 31(6):1202-12.
Score: 0.004
-
Targeted glycoprotein enrichment and identification in stromal cell secretomes using azido sugar metabolic labeling. Proteomics Clin Appl. 2013 Jun; 7(5-6):367-71.
Score: 0.004
-
Multiple signal transduction pathways mediate c-Jun protein phosphorylation. Cell Growth Differ. 1993 May; 4(5):377-85.
Score: 0.004
-
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013 Apr; 14(4):371-82.
Score: 0.004
-
Suramin inhibits growth and yet promotes insulin-like growth factor II expression in HepG2 cells. Cancer Res. 1993 Feb 01; 53(3):652-7.
Score: 0.004
-
Affinity-purified c-Jun amino-terminal protein kinase requires serine/threonine phosphorylation for activity. J Biol Chem. 1992 Aug 25; 267(24):17001-5.
Score: 0.004
-
Phorbol ester-induced amino-terminal phosphorylation of human JUN but not JUNB regulates transcriptional activation. Proc Natl Acad Sci U S A. 1992 Aug 01; 89(15):7247-51.
Score: 0.004
-
Induction of differentiation and c-jun expression in human leukemic cells by okadaic acid, an inhibitor of protein phosphatases. J Cell Physiol. 1992 May; 151(2):415-26.
Score: 0.004
-
Regulation of the p58GTA cell division control-related protein kinase during phorbol 12-myristate 13-acetate-induced terminal differentiation of U937 cells. Oncogene. 1992 Mar; 7(3):501-6.
Score: 0.004
-
Upstream regions of the c-jun promoter regulate phorbol ester-induced transcription in U937 leukemic cells. Nucleic Acids Res. 1992 Feb 25; 20(4):897-902.
Score: 0.004
-
Bryostatin 1: a potential anti-leukemic agent for chronic myelomonocytic leukemia. Leukemia. 1991 Apr; 5(4):283-7.
Score: 0.004
-
Regulation of c-jun expression and AP-1 enhancer activity by granulocyte-macrophage colony-stimulating factor. J Biol Chem. 1991 Mar 25; 266(9):5670-5.
Score: 0.004
-
Multiple doses of diacylglycerol and calcium ionophore are necessary to activate AP-1 enhancer activity and induce markers of macrophage differentiation. J Biol Chem. 1990 Oct 25; 265(30):18166-71.
Score: 0.003
-
Differentiation and growth modulation of chronic myelogenous leukemia cells by bryostatin. Cancer Res. 1990 Sep 01; 50(17):5520-5.
Score: 0.003
-
Role of thoracic radiotherapy combined with chemotherapy in limited stage small cell lung cancer (SCLC). A randomized multicenter phase III trial. Onkologie. 1990 Aug; 13(4):253-8.
Score: 0.003
-
Overexpression of protein kinase C beta 1 is not sufficient to induce factor independence in the interleukin-3-dependent myeloid cell line FDC-P1. Oncogene. 1990 Aug; 5(8):1243-6.
Score: 0.003
-
Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009 Jul 01; 27(19):3133-40.
Score: 0.003
-
Lack of phosphorylation of lipocortin I in A431 epidermoid carcinoma cells treated with phorbol esters. Biochem Biophys Res Commun. 1989 Apr 28; 160(2):474-9.
Score: 0.003
-
Varied differentiation responses of human leukemias to bryostatin 1. Cancer Res. 1989 Mar 01; 49(5):1287-93.
Score: 0.003
-
Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem. 2009 Jan 08; 52(1):74-86.
Score: 0.003
-
Leukemia-differentiating activity expressed by the human melanoma cell line LD-1. Leuk Res. 1988; 12(3):217-25.
Score: 0.003
-
Phase I dose escalation study of vinorelbine and topotecan combination chemotherapy in patients with recurrent lung cancer. BMC Cancer. 2007 Dec 20; 7:231.
Score: 0.003
-
Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial. BMC Cancer. 2007 Dec 03; 7:221.
Score: 0.003
-
Tyrosine kinase and phosphotyrosine phosphatase activity in human promyelocytic leukemia cells and human polymorphonuclear leukocytes. Blood. 1987 Aug; 70(2):356-62.
Score: 0.003
-
Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma. Cancer Biol Ther. 2007 Jul; 6(7):1015-7.
Score: 0.003
-
Bryostatin induces changes in protein kinase C location and activity without altering c-myc gene expression in human promyelocytic leukemia cells (HL-60). Oncogene. 1987 May; 1(2):111-8.
Score: 0.003
-
Production of multilineage hemopoietic growth-stimulating activities by a human melanoma cell line. Exp Hematol. 1986 Oct; 14(9):867-72.
Score: 0.003
-
Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis. Cancer Biol Ther. 2006 Aug; 5(8):1015-21.
Score: 0.003
-
AML1/RUNX1 phosphorylation by cyclin-dependent kinases regulates the degradation of AML1/RUNX1 by the anaphase-promoting complex. Mol Cell Biol. 2006 Oct; 26(20):7420-9.
Score: 0.003
-
Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc Natl Acad Sci U S A. 1986 Mar; 83(5):1334-8.
Score: 0.003
-
A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer. 2005 Apr 01; 103(7):1431-8.
Score: 0.002
-
[Staging and study procedure in small-cell bronchial carcinoma]. Dtsch Med Wochenschr. 1984 Jun 08; 109(23):910-2.
Score: 0.002
-
[Therapy of small-cell bronchial carcinoma]. Dtsch Med Wochenschr. 1984 Jun 08; 109(23):913-5.
Score: 0.002
-
Overexpression of the oncogenic kinase Pim-1 leads to genomic instability. Cancer Res. 2003 Dec 01; 63(23):8079-84.
Score: 0.002
-
The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem. 2003 Nov 14; 278(46):45358-67.
Score: 0.002
-
A novel mitogen-activated protein kinase phosphatase is an important negative regulator of lipopolysaccharide-mediated c-Jun N-terminal kinase activation in mouse macrophage cell lines. Mol Cell Biol. 2001 Oct; 21(20):6999-7009.
Score: 0.002
-
Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Res. 2000 Nov; 6(11):4205-8.
Score: 0.002
-
A Phase I trial of bryostatin-1 in children with refractory solid tumors: a Pediatric Oncology Group study. Clin Cancer Res. 1999 Sep; 5(9):2344-8.
Score: 0.002
-
Regulation of the c-jun gene in p210 BCR-ABL transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase. Blood. 1998 Oct 01; 92(7):2450-60.
Score: 0.001
-
Stress-activated protein kinases bind directly to the delta domain of c-Jun in resting cells: implications for repression of c-Jun function. Oncogene. 1995 Mar 02; 10(5):849-55.
Score: 0.001
-
Interaction of the growth hormone receptor cytoplasmic domain with the JAK2 tyrosine kinase. Endocrinology. 1994 Nov; 135(5):2228-39.
Score: 0.001
-
Co-purification of mitogen-activated protein kinases with phorbol ester-induced c-Jun kinase activity in U937 leukaemic cells. Oncogene. 1993 Feb; 8(2):407-15.
Score: 0.001
-
Antineoplastic bryostatins are multipotential stimulators of human hematopoietic progenitor cells. Proc Natl Acad Sci U S A. 1987 Dec; 84(23):8483-7.
Score: 0.001
-
Enolase isoenzymes as tumour markers. J Clin Chem Clin Biochem. 1986 Dec; 24(12):1009-16.
Score: 0.001
-
[Neo-adjuvant chemotherapy of head and neck cancer]. Dtsch Med Wochenschr. 1986 Jul 11; 111(28-29):1097-100.
Score: 0.001